Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, shared Katy Beckermann’s, Medical Director of GU Clinical Research at Tennessee Oncology, post on X, adding:
“Just Out: Couldn’t have said it better. IMDC very favorable risk is a new category of metastatic kidney cancer that needs VEGF-based therapy. IO alone may not be enough. Great work Martín Zarbá, Toni Choueiri, Tom Powles, Rana McKay, Eddy Saad, UCalgaryMedicine, JAMA Network Open.”
Quoting Katy Beckermann’s post:
“Not all IMDC favorable-risk RCC is the same.
Tier 1 (‘very favorable’): KPS ≥90%, diagnosis to treatment ≥3 yrs, no brain/liver/bone mets. Median OS 79 vs 54 months for tier 2, and molecularly more angiogenic, less immunogenic.
JAMA Netw Open (n=641 IMDC favorable-risk mRCC): ‘very favorable’ tier IO-IO 2-yr OS 73.1% vs 89.1%
IO-VE vs 92.4% VEGF-TT in tier 1 (HR 3.64, p=0.005)
Molecular data: tier 1 tumors are less immunogenic
Why this matters: IMDC favorable risk isn’t a single population very favorable patients have cold tumors and may need VEGF-based regimens .”
Other articles featuring Daniel Heng and Katy Beckermann on OncoDaily.